Skip to main content
logo
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
5.68
-0.29 (-4.86%)
Oct 16, 2026, 3:56 PM EDT - Market open

Kyverna Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
351537161---
Market Cap Growth
20.16%232.60%----
Enterprise Value
185371-151---
Last Close Price
5.979.403.74---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
2.222.310.61---
P/TBV Ratio
2.202.310.61---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.200.130.030.190.230.09
Net Debt / Equity Ratio
-1.00-1.08-1.04-0.99-0.87-1.13
Net Debt / EBITDA Ratio
1.061.491.980.801.432.74
Net Debt / FCF Ratio
1.051.632.380.911.113.01
Asset Turnover
----0.09-
Quick Ratio
8.757.658.472.904.294.78
Current Ratio
9.067.768.613.064.464.84
Return on Equity (ROE)
-87.24%-64.67%-80.74%-125.95%-52.95%-
Return on Assets (ROA)
-44.51%-35.47%-46.93%-54.89%-24.10%-
Return on Capital Employed (ROCE)
-80.70%-66.00%-52.60%-112.80%-53.50%-37.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-41.98%-30.04%-78.95%---
FCF Yield
-43.74%-28.62%-72.13%---
Buyback Yield / Dilution
-22.58%-15.46%-5590.81%-47.89%-71.30%-
SEC Filings: 10-K · 10-Q